Clinical trials: Heart Failure NYHA Class III, active
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses.
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, End-stage Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- ESHF-WHRT (NCT06299176)
- Testing
- Whole Heart Radiation Therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Univentricular Heart, Congenital Heart Disease
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease.
- Conditions
- Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT05647213
- Testing
- iPSC-CL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HeartWorks, Inc.
Heart Failure, Heart Failure NYHA Class III
Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF)
The Narrative Intervention for Chronic Illness-Heart Failure (NICI-HF) offers an asynchronous interactive text behavioral health intervention to advance behavioral health equity by facilitating access to care for people adjusting…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NICI-HF (NCT06097481)
- Testing
- Narrative Intervention for Chronic Illness-Heart Failure, Attention Control
- Volunteers
- 300 people
- Sponsor
- University of Colorado, Denver
Heart Failure, Heart Failure NYHA Class II
Heart Failure Management for Patient With CIED Remotely Monitored
This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- PROACT-HF (NCT07247032)
- Testing
- SmartSignalHF, HF RM standard of care
- Where
- France
- Volunteers
- 1,132 people
- Sponsor
- Implicity
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Trial name
- NCT07864558
- Testing
- Individualized myPACE pacemaker programming
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tufts Medical Center
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Sustaining Home Heart Failure Palliative Care in Rural Appalachia
The aim of this mixed methods randomized controlled trial is to test the integrated nurse-led intervention bundle for family home care management of end-stage heart failure and palliative care in rural Appalachia.
- Trial name
- NCT06791850
- Testing
- HF-FamPALhomeCARE
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- West Virginia University
Heart Failure, Heart Failure New York Heart Association Class III
Inspiratory Muscle Training in Hospitalized Patients With Heart Failure Awaiting Advanced Therapies
The primary objective of this study is to evaluate the feasibility and safety of inspiratory muscle training (IMT) when implemented as part of routine inpatient physical therapy care in patients undergoing evaluation for advanced…
- Conditions
- Heart Failure, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV
- Trial name
- NCT07862738
- Testing
- POWERbreathe KH2, Usual Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Tricuspid Regurgitation, Heart Failure NYHA Class III
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
The use of implantable left ventricular assist devices (LVAD) has increased over the last decade; partly because the newer continuous flow pumps feature a smaller design and better durability.
- Conditions
- Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT02537769
- Testing
- Left ventricular assist device (LVAD), Tricuspid Valve Repair (TVR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors.
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Trial name
- EMAS-HF (NCT05885607)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Heart Failure NYHA Class III, Heart Failure
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure.
- Trial name
- LOWER-PAP (NCT06783335)
- Testing
- Cordella PA Sensor System, Standard of Care Pharmacologic Therapy
- Where
- United States
- Volunteers
- 2,150 people
- Sponsor
- Endotronix, Inc.
Heart Failure, Heart Failure NYHA Class I
Promoting Well-being and Health in Heart Failure
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24…
- Conditions
- Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT04829617
- Testing
- PP-MI Intervention, MI-alone Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Massachusetts General Hospital
Heart Failure, NYHA Class III Heart Failure
NORM-HF Pivotal Study
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF…
- Conditions
- Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
- Trial name
- NORM-HF (NCT07574593)
- Testing
- IVC Sensor
- Where
- 25 sites in United States
- Volunteers
- 800 people
- Sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
Heart Failure, Heart Failure NYHA Class III
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms.
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
- Trial name
- EASE HF2 (NCT06859970)
- Testing
- PAS-C System
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- InterShunt Technologies, Inc.
Heart Failure
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care.
- Trial name
- PAS (NCT03970343)
- Testing
- OPTIMIZER Smart System
- Where
- 90 sites in United States
- Volunteers
- 620 people
- Sponsor
- Impulse Dynamics
Heart Failure, Heart Failure NYHA Class II
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF < 50%…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- BENEFIT-HF (NCT07232030)
- Testing
- Barostim System, Usual care medical management
- Where
- 22 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- CVRx, Inc.
Heart Failure, Heart Failure NYHA Class IV
Association Between the Sit-To-Stand Test and the Prognosis of Patients With Heart Failure
Introduction: Heart failure (HF), among cardiovascular diseases, is the disease that has been increasing its incidence and prevalence the most in recent years in the world population, due to the aging of the population.
- Conditions
- Heart Failure, Heart Failure NYHA Class IV, Heart Failure; With Decompensation, Heart Failure NYHA Class III
- Trial name
- NCT07045649
- Testing
- 1-minute sit-to-stand test
- Where
- Brazil
- Volunteers
- 68 people
- Sponsor
- Centro Universitário Augusto Motta
Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in…
- Trial name
- BRIGHTEN-HF (NCT07209098)
- Testing
- Cardiac Contractility Modulation (CCM)
- Where
- United States
- Volunteers
- 4,200 people
- Sponsor
- Impulse Dynamics
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CardioMEMS HF System Real-World Evidence Post-Approval Study
The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.
- Trial name
- NCT06306573
- Testing
- CardioMEMS HF System
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Congestive Heart Failure
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and…
- Trial name
- NECTAR-HF (NCT01385176)
- Testing
- Implant of investigational device system, Titration during the randomization phase, Titration after the randomization phase
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation